MALMÖ, SWEDEN / ACCESSWIRE / October 24, 2024 / Ascelia Pharma (STO:ACE) Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that its latest scientific abstract, titled "SPARKLE: A Multicenter, Open-label Study to Evaluate the Safety and Diagnostic Efficacy of ACE-MBCA (Orviglance) in Patients with Known or Suspected Focal Liver Lesions and Severe Renal Impairment," has been accepted as part of the Late-Breaking Science Posters session at the prestigious American Society of Nephrology Kidney Week Congress 2024, taking place from 23-27 October in San Diego, US.
The abstract highlights the significant findings from the SPARKLE study on the safety and efficacy of Orviglance and demonstrates that it improves diagnostic efficacy on suspected or known liver lesions (including liver cancer and metastasis) for patients with severe kidney impairment who currently lack alternatives to gadolinium-based contrast enhanced MRI.
"We are thrilled to have our research recognized by such a renowned congress," said Dr. Annalaura Chiocchini, first author of the abstract and Nephrologist at University of Bologna Sant' Orsola Malpighi, Italy, "This acceptance is a testament to the hard work and dedication of our research team and to the global effort put in the SPARKLE study recruitment and conduct."
"The acceptance of the abstract by the Kidney Week Congress underscores that the medical community in this key stakeholder group supports the need for an alternative to gadolinium-based contrast agents for patients with reduced kidney function ", says Andreas Norlin, CSO of Ascelia Pharma.
The presentation will be held on October 24, 2024, from 10:00 AM to 12:00 PM, and will be part of the Late-Breaking Science Posters session.
Contacts
Magnus Corfitzen, CEO
Email: [email protected]
Tel: +46 735 179 118
Julie Waras Brogren, Deputy CEO (Finance, Investor Relations & Commercial)
Email: [email protected]
Tel: +46 735 179 116
This information was submitted for publication, through the agency of the contact persons set out above.
About us
Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates - Orviglance and Oncoral - in clinical development. Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit http://www.ascelia.com.
About Orviglance
Orviglance (manganese chloride tetrahydrate) is a novel oral contrast agent for MR-imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with reduced kidney function. These patients are at risk of serious side effects from the currently available class of gadolinium-based contrast agents. Orviglance, has been granted an Orphan Drug Designation by the US Food and Drug Administration (FDA). A clinical program of nine studies, including the pivotal global Phase 3 study SPARKLE, has successfully been completed with strong and consistent efficacy and safety results.
Attachments
SOURCE: Ascelia Pharma